The renaissance of psychedelics in modern psychiatry: a new breakthrough or the myth of a “magic bullet”? DOI Open Access
Valentin Yurievich Skryabin

Neurology Bulletin, Journal Year: 2025, Volume and Issue: LVII(1), P. 89 - 95

Published: March 14, 2025

In recent years, there has been a significant surge of interest in psychedelic research. These studies encompass both neuroscience and their potential clinical applications. This phenomenon, often referred to as the "Psychedelic Renaissance", includes on compounds such psilocybin, MDMA, DMT, LSD used for treatment depression, post-traumatic stress disorder, anxiety, obsessive-compulsive disorders. substances offer novel paradigm due rapid therapeutic effect ability induce long-term mental state changes, particularly when supported by appropriate psychotherapeutic interventions. At same time, many that praise psychedelics remain methodologically weak, limiting integration these into medical practice. article provides discussion current perspectives critical review existing scientific evidence. It explores historical context use, including early research therapy methodology with ketamine developed Russia Professor E.M. Krupitsky. Key challenges are discussed detail, lack adequate placebo controls standardized dosing, small sample sizes, influence contextual factors may confound study outcomes. Based this analysis, author encourages Russian psychiatrists critically assess available data develop balanced approach use therapy, considering quality evidence base specifics regulatory framework.

Language: Английский

Editorial for psychedelic and psychedelic and psychedelic-like states DOI Creative Commons
David B. Yaden

International Review of Psychiatry, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 6

Published: Feb. 13, 2025

Language: Английский

Citations

0
Further education in psychedelic-assisted therapy – experiences from Switzerland DOI Creative Commons
Helena D. Aicher, Felix Müller,

Peter Gasser

et al.

BMC Medical Education, Journal Year: 2025, Volume and Issue: 25(1)

Published: March 5, 2025

The growing interest in psychedelic-assisted therapy (PAT) for treating psychiatric disorders such as treatment-resistant depression, PTSD, and anxiety has led to an increasing demand specialized training. In Switzerland, MDMA, psilocybin, LSD are applied the framework of limited medical use exceptional treatment options since 2014. Swiss Medical Association Psychedelic Therapy (SÄPT) been a key player addressing need education, offering comprehensive, three-year training program physicians psychologists. This curriculum integrates theoretical knowledge with hands-on experience, emphasizing therapeutic relationship, ethical considerations, management altered states consciousness induced by psychedelics. article gives overview structure addresses topics covered through teaching retreats focusing on practical learning. However, these programs far exceeds supply. gap is expected widen psychedelics potentially become regulated prescription medications. response, several organizations have expanded their educational offerings, including further education trainings, workshops, conferences, symposia. Overall, there more comprehensive accessible meet demand. evolving landscape psychedelic research, regulatory changes, diverse patient populations require flexible adaptive models. As field progresses, it essential establish certification standards ensure continued quality safe effective PAT clinical trials practice.

Language: Английский

Citations

0
The renaissance of psychedelics in modern psychiatry: a new breakthrough or the myth of a “magic bullet”? DOI Open Access
Valentin Yurievich Skryabin

Neurology Bulletin, Journal Year: 2025, Volume and Issue: LVII(1), P. 89 - 95

Published: March 14, 2025

In recent years, there has been a significant surge of interest in psychedelic research. These studies encompass both neuroscience and their potential clinical applications. This phenomenon, often referred to as the "Psychedelic Renaissance", includes on compounds such psilocybin, MDMA, DMT, LSD used for treatment depression, post-traumatic stress disorder, anxiety, obsessive-compulsive disorders. substances offer novel paradigm due rapid therapeutic effect ability induce long-term mental state changes, particularly when supported by appropriate psychotherapeutic interventions. At same time, many that praise psychedelics remain methodologically weak, limiting integration these into medical practice. article provides discussion current perspectives critical review existing scientific evidence. It explores historical context use, including early research therapy methodology with ketamine developed Russia Professor E.M. Krupitsky. Key challenges are discussed detail, lack adequate placebo controls standardized dosing, small sample sizes, influence contextual factors may confound study outcomes. Based this analysis, author encourages Russian psychiatrists critically assess available data develop balanced approach use therapy, considering quality evidence base specifics regulatory framework.

Language: Английский

Citations

0